For example, a previous study showed that the 72% of LARC patients who tested negative for XRCC2 expression in cancer tissues had good pathologic responses and prognoses following neoRT; however, the other 28% of patients who tested negative for XRCC2 developed radioresistance and had poor prognoses [5]. The gene discussed is XRCC2; the disease is cancer.